Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
第一作者:
Ji-Yeon,Kim
第一单位:
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
作者:
主题词
乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);人类(Humans);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);预后(Prognosis);喹唑啉类(Quinazolines);RNA, 信使(RNA, Messenger)
DOI
10.1007/s10549-020-05891-0
PMID
32860168
发布时间
2021-06-23
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文